Login / Signup

Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.

Chiara De PhilippisCristina ZucchinettiDaniele ManninaMauro KramperaPier Luigi Luigi ZinzaniAnnalisa ChiappellaAlice di RoccoEnrico OrciouloMaria Chiara TisiFlavio PistoleseLaura GiordanoArmando SantoroStefania Bramanti
Published in: Bone marrow transplantation (2024)
Keyphrases
  • diffuse large b cell lymphoma
  • epstein barr virus
  • healthcare
  • palliative care
  • quality improvement
  • cell fate
  • acute lymphoblastic leukemia
  • type diabetes
  • adipose tissue
  • metabolic syndrome
  • chronic pain